Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry.
Bernardo M, Cabrera B, Arango C, Bioque M, Castro-Fornieles J, Cuesta MJ, Lafuente A, Parellada M, Saiz-Ruiz J, Vieta E. Bernardo M, et al. Among authors: lafuente a. Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jul-Sep;12(3):135-140. doi: 10.1016/j.rpsm.2019.03.001. Epub 2019 May 16. Rev Psiquiatr Salud Ment (Engl Ed). 2019. PMID: 31103407 Review. English, Spanish. No abstract available.
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project.
Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E, Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M; PEPs GROUP. Bioque M, et al. Among authors: lafuente a. Int J Neuropsychopharmacol. 2016 Mar 31;19(4):pyv121. doi: 10.1093/ijnp/pyv121. Print 2016 Apr. Int J Neuropsychopharmacol. 2016. PMID: 26506856 Free PMC article.
Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis.
Gassó P, Mas S, Bioque M, Cabrera B, Lobo A, González-Pinto A, Díaz-Caneja CM, Corripio I, Vieta E, Castro-Fornieles J, Sarró S, Mané A, Sanjuan J, Llerena A, Lafuente A, Saiz-Ruiz J, Bernardo M; PEPs Group. Gassó P, et al. Among authors: lafuente a. J Psychopharmacol. 2018 Jun;32(6):702-710. doi: 10.1177/0269881118773026. Epub 2018 May 16. J Psychopharmacol. 2018. PMID: 29767567
Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.
Bioque M, Mas S, Costanzo MC, Cabrera B, Lobo A, González-Pinto A, Rodriguez-Toscano E, Corripio I, Vieta E, Baeza I, Ibáñez Á, Fraile MG, Cuesta MJ, Mezquida G, Lafuente A, Bernardo M; PEPs GROUP. Bioque M, et al. Among authors: lafuente a. Eur Neuropsychopharmacol. 2019 Jun;29(6):786-794. doi: 10.1016/j.euroneuro.2019.04.005. Epub 2019 May 7. Eur Neuropsychopharmacol. 2019. PMID: 31076188
Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort.
Mas S, Gassó P, Rodríguez N, Cabrera B, Mezquida G, Lobo A, González-Pinto A, Parellada M, Corripio I, Vieta E, Castro-Fornieles J, Bobes J, Usall J, Saiz-Ruiz J, Contreras F, Parellada E, Bernardo M; PEPs group. Mas S, et al. Acta Psychiatr Scand. 2020 Jun;141(6):541-552. doi: 10.1111/acps.13131. Epub 2019 Dec 5. Acta Psychiatr Scand. 2020. PMID: 31746462
Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period.
Gassó P, Arnaiz JA, Mas S, Lafuente A, Bioque M, Cuesta MJ, Díaz-Caneja CM, García C, Lobo A, González-Pinto A, Parellada M, Corripio I, Vieta E, Castro-Fornieles J, Mané A, Rodríguez N, Boloc D, Saiz-Ruiz J, Bernardo M; PEPs Group. Gassó P, et al. Among authors: lafuente a. J Psychopharmacol. 2020 May;34(5):514-523. doi: 10.1177/0269881120903462. Epub 2020 Feb 3. J Psychopharmacol. 2020. PMID: 32009515
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
Mas S, Gassó P, Torra M, Bioque M, Lobo A, González-Pinto A, Olmeda MS, Corripio I, Vieta E, Castro-Fornieles J, Rodriguez-Jimenez R, Bobes J, Usall J, Llerena A, Saiz-Ruiz J, Bernardo M, Lafuente A, PEPs Group. Mas S, et al. Among authors: lafuente a. Eur Neuropsychopharmacol. 2017 Jul;27(7):647-656. doi: 10.1016/j.euroneuro.2017.03.012. Epub 2017 Apr 5. Eur Neuropsychopharmacol. 2017. PMID: 28389049
Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.
Boloc D, Rodríguez N, Torres T, García-Cerro S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M, Gassó P, Lafuente A, Mas S, Arnaiz JA. Boloc D, et al. Among authors: lafuente a. Psychopharmacology (Berl). 2020 Jul;237(7):2151-2159. doi: 10.1007/s00213-020-05526-8. Epub 2020 May 7. Psychopharmacology (Berl). 2020. PMID: 32382784 Clinical Trial.
Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data.
Martínez-Pinteño A, Gassó P, Prohens L, Segura AG, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M, Lafuente A, Mas S, Rodríguez N. Martínez-Pinteño A, et al. Among authors: lafuente a. Front Pharmacol. 2021 Aug 13;12:729474. doi: 10.3389/fphar.2021.729474. eCollection 2021. Front Pharmacol. 2021. PMID: 34483940 Free PMC article.
295 results